Board summary
Key figures
45,196
Registered population
59.7% aged 18–64
17.5%
Aged 65+
ICB 14.9% · England 17.9%
46.0%
In IMD quintile 1
ICB 40.7% · England 21.0%
~19,032
Core20 residents (est.)
Resident basis; registered basis ~21,509 · see page 3
6,843
Hypertension register
+3.87% in 3 yrs · England +5.60%
517
SMI register
16.6% of Rochdale (LAD)'s
1,241
COPD register
Reviews +0.76% in 3 yrs
Forecast to 2030
7,650
Hypertension patients, 2030
+807 on today
74.9%
QRISK ≥20% on statins, 2030
+4.53pp over 3 yrs
4.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Core20 deprivation spans 41.9 pp across practices.
Core20 share ranges from 31.2% at The Junction Surgery to 73.1% at Woodside Medical Centre (6,468 estimated patients), focusing need in specific lists.
Learning disability and dementia registers contracted.
From 2023 to 2025, learning disability prevalence fell 12.3% (England +5.4%; 276 patients) and dementia fell 0.4% (England +6.0%), which may reflect coding gaps.
Older-adult blood pressure and asthma reviews lead.
BP control aged 80+ is 85.0% (England 81.2%) and asthma reviews reach 71.6% (England 65.7%), though about 880 asthma patients remain unreviewed.
Population, age and ethnicity
Registered patients include 10,338 aged 0-17 and 7,889 aged 65+, potentially shaping dual demand
Across 45,196 registered patients, 22.9% (10,338) are aged 0-17, compared with 23.5% in Rochdale, 21.8% in NHS Greater Manchester Integrated Care Board and 19.6% in England. Those aged 65+ account for 17.5% (7,889 patients), above Rochdale (14.7%) and the ICB (14.9%), but below England (17.9%). The 18-64 band comprises 59.7% (26,969 patients). Recorded Roma residents represent 0.1% and Gypsy or Irish Traveller 0.0%. Projected list growth to 2030 is 1.7% (Rochdale 1.4%, ICB 1.6%, England 2.3%), though observation periods and projection methods are unverified.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rochdale LA) | 2,300 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rochdale LA) | 1,088 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rochdale LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 46.0% PCN-wide and spans 41.9 percentage points across practices
Across Middleton PCN, 46.0% of registered patients live in Core20 areas (England 21.0%, ICB 40.7%, Rochdale 48.0%). Weighted practice share is 47.6%, making practice estimates indicative targeting aids rather than exact headcounts. Core20 share spans 41.9 pp, from 31.2% at The Junction Surgery to 73.1% at Woodside Medical Centre. Concentration is highest at Woodside Medical Centre (73.1%) and Windermere Surgery (68.5%), while volume peaks at Woodside Medical Centre (6,468 estimated patients) and Durnford Medical Centre (3,919). Outreach can balance high-concentration lists against high-volume caseloads across distinct practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
517
SMI register
1.14% recorded prevalence
276
Learning disability register
0.61% recorded prevalence
11
Care homes, 358 beds
In the PCN catchment
9.7%
Provide unpaid care
Rochdale (LAD), Census 2021
The PCN records 517 patients on the severe mental illness register (1.1%, against 1.0% in England) and 276 on the learning disability register (0.6%, matching England at 0.6%). The catchment includes 11 care homes with 358 beds, though bed capacity does not establish registered resident numbers.
Severe mental illness: physical health checks
SMI prevalence is 1.1% (England 1.0%). Annual blood pressure checks reached 84.1% (England 83.4%), though 2023 to 2025 progress fell 0.2 pp (England +4.4 pp); BMI checks reached 82.2% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,843
Hypertension register
+3.87%
Register growth, 3 yrs
Rochdale (LAD) +6.17% · England +5.60%
+2.60pp
BP control, under 80
≤140/90 · +4.21pp aged 80+
+807
More patients by 2030
Forecast 7,650 (16.33%)
Hypertension case-finding and control
MIDDLETON PCN records 6,843 patients with hypertension (15.1% prevalence), compared with England (15.2%), NHS Greater Manchester Integrated Care Board (14.4%) and Rochdale (15.6%). Unadjusted prevalence against comparators yields a modelled gap range of +40 to +217 patients. From 2023 to 2025, register growth was +3.9% (England +5.6%; Rochdale +6.2%). Blood pressure monitoring reached 90.2% (England 90.0%), and BP control in patients aged 80+ reached 85.0% (England 81.2%; Rochdale 83.8%). Across practices, prevalence spans from 12.9% at Rochdale Road Medical Centre to 17.3% at Durnford Medical Centre. Slower register growth than borough comparators may reflect under-detection, which practice clinical audits could verify.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy reach 64.8% (England 63.6%; Rochdale 68.3%). Statin therapy reaches 75.1% for patients with diabetes aged 40+ without CVD (England 73.2%; Rochdale 76.6%). Trailing borough lipid coverage may reflect treatment gaps, which clinical audits could verify.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 88,308 | £2.00 | £1.94 | £1.86 | £176,616 |
| Cardiovascular (all), 2025 | 113,500 | £3.40 | £3.15 | £3.33 | £385,900 |
Lipid-regulating drugs in 2026 cost £2.00 per item across 88,308 items (£176,616 annual spend). The PCN spends £12,363 more than at England's unit cost (£1.86) and £5,298 more than at NHS Greater Manchester Integrated Care Board's unit cost (£1.94). Higher unit costs than England could reflect local formulary choices, which prescribing audits could review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.97%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.17%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.4% (England 6.6%), covering 3,108 patients, with 71.6% reviewed in the last 12 months (England 65.7%), leaving about 880 patients unreviewed. Asthma management items reached 2,177 per 1,000 aged 5-19 (England 1,488; Rochdale 1,888). COPD prevalence is 2.8% (England 1.9%, 1,241 patients) with 79.0% reviewed (England 76.4%). High paediatric prescribing may reflect underlying disease burden, which inhaler adherence audits could evaluate.
Cancer register and children's immunisation
Cancer prevalence is 3.9% (England 3.8%), covering 1,739 patients. In Q1 2025/26, 6-in-1 coverage at 24 months reached 94.9% (England 92.2%). At age 5, MMR dose 2 was 80.8% (England 82.8%), sitting below the 95.0% target by 14.2 pp, with an 8.3 pp difference from dose 1 (89.1%). The 4-in-1 booster reached 78.2% (England 80.9%), below the 95.0% target by 16.8 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028 (about 2,270 extra early-stage cases needed annually). Known-stage coverage was 70.8% (11,679 of 16,492; England 67.0%). Early-stage diagnosis reached 40.4% in lung and 46.3% in bowel, but 82.5% in breast. System data reflects wider pathway presentation, not PCN delivery. Lower early detection in bowel compared to England and the distance to the 75.0% ambition across cancer types highlight an opportunity to review referral and safety-netting pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Northern Care Alliance NHS Foundation Trust reached 78.6% on the 62-day standard (6.4 pp below the 85.0% standard), above Manchester University NHS Foundation Trust (72.8%), Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). On the 28-day faster diagnosis standard, Northern Care Alliance achieved 75.2%, meeting the 75.0% standard but behind the ICB (79.5%) and England (79.3%). Diagnostic 6+ week waits were 5.1% for MRI and 4.1% for CT (England 21.4% and 9.9%). Provider data reflects acute pathways, not PCN delivery.
| Pathways within standard (%) | Northern Care Alliance | Manchester | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 80.06 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 92.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 72.85 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Manchester | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 5.09 | 11.68 | 0.00 | 21.40 |
| CT | 4.10 | 14.66 | 0.18 | 9.92 |
| Echocardiography | 31.48 | 4.91 | 0.00 | 28.48 |
| Colonoscopy | 40.04 | 4.51 | 1.51 | 30.83 |
| Gastroscopy | 36.48 | 29.35 | 5.45 | 29.02 |
| All 15 DM01 tests | 15.71 | 8.98 | 0.80 | 23.14 |
| Community services activity | Rochdale residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 60,250 | 573,310 |
| Referrals | 9,455 | 94,470 |
| Patients with a contact | 19,345 | 183,535 |
Community services (residents of Rochdale), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65+ accounted for 40.9% of all community service contacts among Rochdale borough residents (24,650 of 60,250 contacts; borough data, not PCN level). Older-age community contacts indicate borough-level demand for intermediate care coordination.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF clinical-domain achievement was 100.0% at Peterloo Medical Centre (England 97.1%) and 90.2% at Windermere Surgery. QOF vaccination and immunisation-domain achievement spanned 28.3 pp, ranging from 15.6% at Rochdale Road Medical Centre to 43.9% at Woodside Medical Centre (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Rochdale Road | 96 | 54.5 | 67.9% | 73.1% | 86.7% |
| Windermere Surgery | 93 | 68.5 | 79.0% | 63.8% | 85.7% |
| Durnford | 107 | 40.4 | 63.4% | 77.4% | 83.7% |
| Junction | 123 | 31.2 | 67.5% | 70.7% | 82.4% |
| Peterloo | 106 | 34.5 | 47.4% | 69.1% | 75.4% |
| Woodside | 118 | 73.1 | 31.7% | 69.9% | 71.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Learning disability registers fell 12.3% over three years while depression prevalence reached 23.1%
Over 2023 to 2025, three-year relative changes trailed national trends most sharply for learning disability prevalence, falling 12.3% (England +5.4%, Rochdale -15.8%), heart failure reviews, falling 2.2% (England +8.7%), and dementia prevalence, falling 0.4% (England +6.0%). Conversely, three-year gains outpaced England for asthma reviews (+10.0% vs +4.4%) and diabetic statin prescribing (+7.6% vs +2.1%). Furthermore, 12-month blood pressure checks for severe mental illness fell 0.2 pp (England +4.4 pp). Prioritising clinical audits across chronic disease registers may help determine whether declining registers reflect genuine epidemiological shifts or unverified recording gaps.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
Dementia register
BP check (SMI)
Stroke register
Asthma reviews
Diabetes statin (no CVD)
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rochdale (LAD) | Asset | PCN | Rochdale (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (358 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 4 | 17 | Places of worship | 24 | 116 |
| Libraries | 2 | 12 | Primary schools (LA maintained) | 11 | 38 |
| Primary academies | 3 | 26 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension case-finding and lipid review
Hypertension prevalence is 15.1% (6,843 patients; Rochdale 15.6%, England 15.2%), giving an unadjusted gap of +40 to +217 patients. QRISK ≥ 20% lipid therapy is 64.8% (Rochdale 68.3%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Learning disability, dementia and SMI audit
From 2023 to 2025, learning disability prevalence fell 12.3% (276 patients, 0.6%; gap -10 to +21) and dementia fell 0.4% (334 patients, 0.7%; gap +19 to +20). SMI BP checks fell 0.2 pp. Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
Pre-school booster and asthma review recall
In Q1 2025/26, age-5 MMR2 is 80.8% (below 95.0% by 14.2 pp) and 4-in-1 is 78.2% (below by 16.8 pp). Asthma reviews reach 71.6%, leaving 882 of 3,108 patients unreviewed. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dual pathway capacity review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach model (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre school immunisation recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| System early diagnosis alignment (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Hypertension case-finding and lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Learning disability, dementia and SMI audit (p12) | Learning disability register · Learning disability: QOF prevalence · Dementia register | 75% annual health checks (Network Contract DES) · Oliver McGowan · 66.7% diagnosis ambition · 95% care plan 2027 | PCN & Practice |
| Option 3 · Pre-school booster and asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
